Two doses; tested against a Madagascar clinical isolate
Imperial College London. Self-amplifying RNA in lipid nanoparticles, encoding F1 and V. The RNA copies itself inside the cell, so a smaller amount of RNA can drive antigen production. Two doses. Mice were challenged with a Madagascar clinical isolate in a bubonic model, reported in 2023. Still animals only. Imperial is a university, not a listed company.
Preclinical · bubonic. Phase 3 is empty here, as it is for every programme in the set.
A mark at 2023. Labelled “2023” on the briefing. Not a forecast.
Analyst card
- Bubonic mouse model, Madagascar clinical isolate. Pneumonic challenge is not the 2023 result used here.
- Not reported. F1 and V are both encoded.
- Lipid nanoparticle. The RNA is self-amplifying.
- Two doses. Site not stated.
- saRNA in lipid nanoparticles. Cold-chain requirement is not stated.
- Not reported. No time-to-protection figure is in the briefing.
- Plague only.
- No survival percentage in the briefing.
- Mouse data only. The Madagascar isolate is not described here as drug-resistant.
Pipeline record
- Imperial College London. A university, not a listed company.
- Self-amplifying RNA in lipid nanoparticles, encoding F1 and V. The RNA copies itself in the cell, so the RNA dose can be smaller.
- Two doses.
- A Madagascar clinical isolate, bubonic mouse model, reported in 2023. Still animals only.
News
Checking today’s headlines.
Latest intel
Checking Europe PMC.
PubMed
Checking today’s index.
- saRNA
Self-amplifying RNA copies itself inside the cell, so a smaller dose can drive antigen production. The single candidate here is still in animals.
- UK — Imperial College London
- United Kingdom
- Bubonic
- Preclinical · bubonic
- 2023
- F1V / LcrV